Parnassus Investments LLC Lowers Position in IQVIA Holdings Inc. (NYSE:IQV)

Parnassus Investments LLC decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 20.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 352,543 shares of the medical research company’s stock after selling 92,612 shares during the quarter. Parnassus Investments LLC owned 0.19% of IQVIA worth $83,542,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of IQV. PGGM Investments increased its holdings in shares of IQVIA by 55.8% in the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock worth $2,553,000 after buying an additional 4,326 shares during the last quarter. Quadrature Capital Ltd purchased a new position in shares of IQVIA in the 1st quarter worth about $3,365,000. Simplify Asset Management Inc. increased its position in shares of IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after purchasing an additional 3,894 shares during the last quarter. Raymond James & Associates raised its holdings in shares of IQVIA by 0.7% during the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock valued at $169,231,000 after buying an additional 5,417 shares in the last quarter. Finally, UniSuper Management Pty Ltd lifted its position in IQVIA by 253.0% in the 1st quarter. UniSuper Management Pty Ltd now owns 6,029 shares of the medical research company’s stock worth $1,525,000 after buying an additional 4,321 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This represents a 6.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts have commented on the stock. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Redburn Atlantic began coverage on IQVIA in a research note on Monday, October 14th. They set a “buy” rating and a $276.00 price objective on the stock. Deutsche Bank Aktiengesellschaft lowered their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Morgan Stanley lowered their price objective on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Finally, Argus upgraded shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $259.13.

IQVIA Stock Down 0.8 %

NYSE:IQV opened at $191.19 on Tuesday. The firm’s 50-day moving average price is $225.96 and its 200-day moving average price is $228.02. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The company has a market capitalization of $34.70 billion, a PE ratio of 25.09, a P/E/G ratio of 1.98 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.